A Pharmacogenomics Test for the administration of warfarin

The CYP2C9 & VKORC1 genes are tested in order to both determine the metabolic pathway of the drug substance Warfarin and the optimal starting dose to the patient. Warfarin is given to patients to control severe thrombolytic conditions.

Why testing is important before the administration of Warfarin.

According to FDA guidelines:

  • A reduced dose of warfarin is required in patients with CYP2C9 and/or VKORC1 genetic polymorphisms that result in limited activity.
  • Pharmacogenetic diagnostic tests on CYP2C9 and VKORC1 at the start of warfarin therapy could reduce the occurrences of severe side effects and improve the achievement of INR stability

*The test is performed on 1 EDTA vial of blood or saliva sample


Frequently Asked Questions

Why should I sign the consent form?

For the use of the patient’s genetic material for testing, ELOT EN ISO9001:2015 and ELOT EN ISO15189:2012 require the written consent of each patient.

Are there any special transportation conditions?

The sample should not be frozen. It should be stored at room temperature (25°C). During the summer period we recommend to have an ice pack in the Kit, which should not directly touch the sample. The saliva sample should simply be transported inside the special Kit, without any other special conditions.

Is the test covered by any public/private insurance?

For information about the cost coverage of the test you should contact your insurance company.

How do I make the payment for the test?

Payment can be made by bank transfer or debit/credit card.

How can I send my sample?

To schedule your sample receipt, please contact us.

How will I receive my results?

Your results are shared with your GP and with you via email.

If you want to send us your sample, please contact us in order to arrange all procedures.

*For more information on scientific content please contact: